IN8BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 USD | -0.96% |
|
+1.95% | -24.64% |
Presenter SpeechAndrew Fleszar (Analysts)All right. Welcome to the B. Riley Virtual Oncology C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Companyâs DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.
Calendar
12/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.04
USD
Average target price
7.6
USD
Spread / Average Target
+630.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.64% | 46.22M | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- Transcript : IN8bio, Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-18-2023 12
